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Abstract
Background—Autoantibodies are of growing interest in cancer research as potential 
biomarkers; yet the determinants of autoimmunity are not well understood. Antinuclear antibodies 
(ANA) are common in the general population, and are more prevalent in women and older adults. 
Here we examined the relationship of ANA with reproductive and hormonal factors in a 
representative sample of U.S. women.
Methods—We analyzed data on reproductive history and exogenous hormone use in relation to 
serum ANA in 2,037 females ages 12 and older from the National Health and Nutrition 
Examination Survey (NHANES; 1999–2004). Estimated ANA prevalences were adjusted for 
sampling weights. Prevalence odds ratios (POR) and 95% confidence intervals (CI) were adjusted 
for age, race and poverty-income-ratio, and models were stratified by menopause status.
Results—In premenopausal women ages 20 and older, ANA prevalence was associated with 
parity (p<0.001; parous versus nulliparous POR=2.0; 95%CI 1.2, 3.4), but in parous women ANA 
did not vary by number of births, age at first birth, years since last birth or breastfeeding. In 
postmenopausal women, ANA prevalence was associated with an older age at menarche (p=0.019; 
age 16–20 versus 10–12 years POR=3.0, 95%CI 1.6, 5.9), but not with parity. Oral contraceptives 
and estrogen therapy were not associated with a higher ANA prevalence.
Conclusions—Childbearing (having had one or more births) may explain age-associated 
elevations in ANA prevalence seen in premenopausal women.
Impact—These findings highlight the importance of considering reproductive history in studies 
of autoimmunity and cancer in women.
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INTRODUCTION
Autoantibodies are of growing interest in cancer research based on their potential as 
diagnostic, therapeutic and etiologic markers across multiple types of cancers (1–4). 
Reactivity to tumor-associated antigens in healthy controls has been described in several 
studies (5–7), but the determinants of autoimmunity to tumors and other self-antigens are 
not well understood.
Self-reactive antibodies to ubiquitous cellular components are considered to be a hallmark of 
systemic autoimmune diseases, and antinuclear antibodies (ANA) are the most common 
assessed in clinical practice. Although ANA may precede the development of systemic 
autoimmune disease in some cases, ANA are also frequently detected in healthy individuals 
and are generally considered to be non-specific markers of autoimmunity in the absence of 
other clinical and laboratory features of autoimmune disease (8, 9). Similar to the female 
predominance in many autoimmune diseases, a higher ANA prevalence is seen in females 
compared to males (10–14). In a sample of the U.S. population ages 12 and older (the 
National Health and Nutrition Examination Survey, NHANES; 1999–2004), 17.8% of 
women versus 9.6% of men were identified as ANA positive (11). Notably, the female to 
male ratio increased during the reproductive years, peaking at ages 40–49, though the higher 
prevalence in females compared to males persisted throughout the later decades.
Reasons for sex differences in autoimmunity are not well understood. Possibilities include 
X-chromosome immune-related genes, fetal microchimerism and differential hormonal and 
reproductive factors (15, 16). To better understand the development of autoimmunity in 
women, we examined associations of reproductive and hormonal factors with ANA 




The study sample included NHANES mobile exam participants ages 12 and older with 
blood specimens, enrolled during 1999–2004, and were a subset of participants selected for 
a study of ANA as previously described (11). The present sample (N=2,037) was limited to 
female participants who had ever menstruated, were not pregnant at the time of blood 
collection, and completed the reproductive history questionnaire. The NHANES protocol 
was approved by a human subjects review board, and written informed consent was obtained 
from all participants.
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Serum ANA were measured by a standardized indirect immunofluorescence assay on HEp2 
cells at a 1:80 dilution as previously described (11). Intensity was graded on a scale of 0 to 
4, and specimens with a score of 3 or 4 were considered positive based on findings from 
commercial ANA reference laboratories (12 positive and two negative controls). Controls 
also included 200 CDC referent sera and unknowns(17). Two independent raters agreed on 
over 95% of readings and repeat testing of a 2% random sample showed >98% concordance.
Exposures and covariates
Data on female reproductive factors and hormone use were collected during the mobile 
examination by computer assisted personal interview. Menstrual histories included age at 
menarche, age at last period, having regular periods (1999–2002) or at least one period 
(2003–4) in the past 12 months, and the reasons for not having regular periods/a period in 
the past 12 months (i.e., recent pregnancy, recent or current breast feeding, menopause, 
irregular periods, and medical conditions or treatments). Reproductive history included 
number of pregnancies and live births. We defined parous women as those who had at least 
one live birth. Because information was not collected on pregnancy losses or stillbirth, being 
nulliparous was defined only by reporting no live births. Questions were also asked about 
age at first and most recent live birth, and ever and total number of babies breastfed at least 
1 month.
Women over age 20 were asked about hysterectomy with or without ovaries removed and 
ages at surgery or removal of ovaries. For women under age 55, we defined premenopausal 
status as having had a period in the past 12 months, but also considered women 
premenopausal if they reported not having had a period due to pregnancy or breastfeeding 
(n=46), irregular periods (n=2) or injectable contraceptives (n=4). We defined 
postmenopausal status as the cessation of periods for at least 12 months (not due to 
pregnancy, breast feeding, irregular periods or injectable contraceptives) or having a 
hysterectomy with both ovaries removed prior to or within 1 year of age at cessation of 
periods. Women who had a simple hysterectomy (retaining at least one ovary) at the 
cessation of periods were considered premenopausal if they were younger than age 55 
(n=54; 6.9% of premenopausal women in the sample) or as having had a natural menopause 
if they were age 55 and older (n=138; 19% of postmenopausal women in the sample). 
Women with both ovaries removed prior to age 55 were classified as having a surgical 
menopause. Menopause type could not be established in some women because the reason 
for the absence of periods was not known or was due to unspecified medical conditions or 
treatments (N=35; “other” menopause type in Table 1). These were excluded from 
subsequent analyses of menopause and menopause-age. Menopause age, assigned based on 
the age at last menstrual period or when the second ovary was removed, could not be 
determined for a subset of women (N=121) due to missing data or surgical removal of the 
uterus with the ovaries left in place prior to reported cessation of periods.
Information about birth control included use of oral contraceptives (age first used, current 
use, duration and age stopped) and Depo-Provera or injectable hormonal contraception. 
Women over age 20 were asked about other non-contraceptive female hormone use 
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(hormone therapy, including pills, patches, or creams, suppositories, or injections), hormone 
type (estrogen only, progestin only, or both estrogen and progestin), age first used, current 
use, and total years used. Responses were combined to derive variables estimating total 
years use of estrogen or progestin.
Covariates included age, race/ethnicity, poverty index ratio (PIR), and overweight or obesity 
(based on measured height and weight used to calculate body mass index ≥25 in adults 20 
and older or using age/sex-specific guidelines for ages 12–19), smoking status and pack-
years (11). Participants were also asked about history of thyroid disease and rheumatoid 
arthritis.
Analyses
We used SAS SURVEY procedures (Version 9.3, SAS Institute Inc., Cary, NC) and SAS-
callable SUDAAN (Version 11, Research Triangle Institute, Research Triangle Park, NC) to 
estimate ANA prevalences accounting for sampling weights to extrapolate to the US 
population. Tests of equality of prevalences across covariate categories were based on 
likelihood ratio tests. Prevalence odds ratios (PORs) and 95% confidence intervals (CI) were 
estimated by logistic regression, adjusting for age, race/ethnicity, and poverty index ratio 
(baseline model). The sample weights were not informative (i.e., not related to the outcome, 
given the covariates). Sample-weighted analyses with non-informative weights can reduce 
statistical power (18), so we set the weights to 1 and used the survey procedures to account 
for clustered sampling and to ensure valid variance estimation. Covariates in the base model 
were included to address potential confounding due to selection bias, and based on prior 
findings in the overall sample (11). In sensitivity analyses, we conducted sample-weighted 
analyses for comparison and also ran models adjusted for NHANES cycle, both of which 
showed reduced precision, but otherwise had little impact on our findings.
We ran additional models to rule out potential confounding; the first added overweight or 
obese body mass index (BMI) and an interaction term for age by BMI to the base model. 
Subsequent models also adjusted for age at menarche, parity, and potential confounders 
relevant to specific exposures (e.g., birth-related factors in parous women and menopause 
characteristics in postmenopausal women). Models were run also adjusting for smoking 
pack-years and current smoking status. Because confounding was not seen, only results from 
the baseline models are shown. We conducted sensitivity analyses excluding women with 
self-reported thyroid disease (N=190) and rheumatoid arthritis (N=109); both groups 
included a greater proportion of postmenopausal women than the full sample (65% versus 
49%). We tested the impact of our assumption that younger (<55 years) women with simple 
hysterectomy (retaining one or more ovaries; n=54) were premenopausal, by considering the 
most extreme scenario, reclassifying them as postmenopausal. Most results were unchanged 
in these analyses, except where noted.
Given the expected differences in reproductive and hormonal factors across the female 
lifespan, we first explored the distribution of ANA and covariates stratified by age (12–19 
years, 20–49 years, and 50 years and over; Table 1). We limited subsequent analyses (Tables 
2 and 3) to women over age 20 and stratified by menopause status, due to differences in the 
questionnaire structure and the lower ANA levels seen in both younger and older 
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postmenopausal women. Based on the observed difference in the parity-ANA association by 
menopause status, we tested the multiplicative interaction through inclusion of a product 
term (parity X menopause) in a model including parity and menopause. To explore the role 
of parity in the increased ANA prevalence with age, we examined ANA prevalence across 
age categories, stratified by parity. We then estimated the linear effect of age in women ages 
12–59 and in women ages 60 and over (empirically based on the inflection point seen in 
Figure 1, when ANA prevalence began to increase in nulliparous women), and tested 
whether adjusting for parity and age at menarche might mediate age-associated increases in 
ANA prevalence in these two age groups.
RESULTS
The ANA test was positive in 351 women with an overall weighted prevalence of 17.6%, 
increasing from 12.4% for ages 12–19 to 17.4% and 19.6% for ages 20–49 and 50+, 
respectively (Table 1). ANA prevalence estimates did not vary significantly by demographic 
factors or BMI, but were higher in women who had ever given birth, including those under 
age 20. In adult women over age 20 with menopause data, lower ANA prevalence was seen 
in both younger and older postmenopausal women (20–49 and 50+ years) compared with 
premenopausal women, but did not vary for surgical versus natural menopause. The lower 
ANA prevalence associated with postmenopausal status persisted in a model adjusting for 
age, race/ethnicity and poverty-index ratio (POR=0.54; 95%CI 0.34, 0.87).
Associations of ANA positivity with reproductive characteristics for women ages 20 and 
older are shown in Table 2, stratified by menopause status. Having a positive ANA was 
associated with being parous in premenopausal (POR=2.0; 95%CI 1.2, 3.4 versus 
nulliparous), but not postmenopausal women (interaction p=0.12), and with later onset of 
menarche (age 16–20 versus 10–12 years: POR=3.0; 95%CI 1.6, 5.9) in postmenopausal 
women. Differences in ANA prevalence were not associated with age at first birth or years 
since last birth, or with age at first birth or breastfeeding (not shown). ANA prevalence was 
not associated with age at natural menopause or with overall age at menopause when 
surgical menopause was included (not shown). Elevated ANA prevalence in the small 
number of women with natural menopause before age 35 (POR=2.12; 95% CI 0.66, 6.79), 
was not seen after excluding those reporting RA (POR=0.85; 95% CI 0.17, 4.23).
In women over age 20, regardless of menopause status, we saw no consistent evidence that 
higher ANA prevalence was associated with oral contraceptives or other exogenous estrogen 
use (Table 3), nor with injectable contraceptives or progestin use (not shown). In 
premenopausal women, adjusted models suggested an inverse association with past oral 
contraceptive use that was not confounded by parity (not shown). But no duration effect was 
seen and this association was attenuated and no longer significant after excluding younger 
women with simple hysterectomy (not shown). Although estimated ANA prevalences did 
not vary by oral contraceptive use in post-menopausal women, adjusted models suggested a 
trend in the opposite direction from pre-menopausal women, which became more 
pronounced with a dose-response for more years of use after excluding women reporting RA 
(not shown).
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Lastly, we explored the relationship of ANA, age, and parity. Figure 1 shows ANA 
prevalence by age, stratified by parity. Across ages 12–19 through 50–59 years, ANA 
prevalence was elevated in parous compared to nulliparous women, but did not increase 
with age. For women age 60 and older, ANA prevalence increased steadily with age 
regardless of parity. Based on this inflection point and the possibility that different factors 
may influence ANA at different points in the lifespan, we ran separate models for younger 
(12–59) and older (60+) women to describe the relationship between age and ANA 
prevalence, with and without adjusting for parity (Figure 2). Results showed that parity 
completely attenuated the age-association in younger women ages (for each increasing 
decade versus ages 12–19, p for trend=0.019 before and p=0.998 after adjusting for parity). 
Adjusting for parity did not impact the age-related increases in ANA prevalence in women 
age 60 and older (not shown), and additional adjustment for age at menarche only slightly 
attenuated the age-trend in older women (p=0.018 before and p=0.065 after adjusting for 
parity and menarche age).
DISCUSSION
Our results suggest that childbearing (i.e., having had at least one live birth) is an important 
determinant of ANA positivity in premenopausal U.S. women, and that age-associated 
elevations in ANA prevalence across the reproductive years in women may be due to the 
increasing prevalence of parity with age. In nulliparous women, the pattern of age-specific 
ANA prevalence appeared strikingly similar to what we previously observed in men (11), 
with a slight decline in the 30s and 40s before rising with age in older adults. By contrast, 
ANA prevalence in parous women remained elevated from ages 12–19 up to age 59 years, 
after which ANA prevalence increased with age for all women regardless of parity. Our 
results do not support the idea that exogenous hormone use contributes to a higher ANA 
prevalence in women overall. Given the potential for confounding or modification by 
systemic autoimmunity in studies of tumor autoimmunity (6, 19–21), our findings highlight 
the need to understand the role of female reproductive factors and hormonal in the 
development of autoimmunity.
Immune self-tolerance is induced and maintained by important developmental mechanisms 
early in life and throughout the lifespan. Low levels of autoantibodies are normal in healthy 
people, but are typically low-affinity and mostly Immunoglobulin (Ig) M isotypes. The gold 
standard ANA assay (immunofluorescence on HEp-2 cells) detects IgG antibodies to 150 to 
200 known autoantigens and others that are as yet undefined. In autoimmune disease, 
autoantibodies are thought to arise from a breakdown in specific immune tolerance to self-
antigens involving both antibody-producing B cells and stimulation by helper T-cells. 
Although a causal role in disease pathogenesis is not fully established for many 
autoantibodies, they often play an critical role in the diagnosis of specific autoimmune 
diseases in the context of clinical phenotypes (22). In patients who develop systemic 
autoimmune diseases, ANA can be detected years prior to diagnosis, with increasing 
antibody levels and specific types predicting the onset of clinical disease (8, 23, 24). Little is 
known about the natural history of ANA in healthy individuals, or the factors contributing to 
the progression from ANA-positivity to an autoimmune pathology and disease. Two studies 
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of healthy individuals showed that ANA persisted in the majority over a 5 year follow-up, 
with little evidence of clinical autoimmune disease (9, 25).
An association of parity with ANA prevalence has not been previously described. Studies 
have focused on infertility and other adverse outcomes associated with pre-pregnancy 
autoimmunity and autoimmune diseases (26), but little is known about the incidence and 
determinants of ANA after pregnancy and throughout the reproductive years in healthy 
women. Our findings are consistent with the idea that the post-partum period is a time of 
increased risk of autoimmunity and autoimmune diseases (27, 28). Pregnancy and childbirth 
induce profound hormonal changes, including large, transient shifts in estrogen and 
progesterone, which both have immune modulating properties (29). Prolactin is another 
pregnancy-related hormone associated with autoimmune diseases (30), but we saw no 
association of breast feeding with ANA.
Other explanations for why parity could increase ANA prevalence include microchimerism 
due to the transfer of fetal cells that can engraft and persist for decades (31). 
Microchimerism has been proposed as a cause of various autoimmune diseases, but the 
findings are inconsistent (32). Survival of fetal chimeric grafts may depend on variation in 
the Major Histocompatibility Complex, and existing grafts may be subject to aging, 
competition or replacement with grafts from subsequent births (33). Thus, lack of a dose-
effect for number of births and ANA is not inconsistent with the idea of microchimerism. 
We also saw no waning of ANA with time since last birth, but this cannot be directly 
assessed in our cross-sectional analysis or disentangled from other aging-related influences 
across such a broad age-range. We cannot rule out the possibility that longer time since last 
birth might contribute to the lack of observed effect of parity on ANA in postmenopausal 
women. Longitudinal studies with ANA measures before, during and after pregnancy, and 
also through the menopausal transition, would be particularly valuable.
Interpreting an association between parity and ANA is also complicated by the possibility 
that autoimmunity and autoimmune diseases can impair fertility or affect childbearing 
choices (34). Women in our study who reported a history of pregnancy and no live births 
had a lower ANA prevalence (n=73; ANA 7.7%; 95% CI 3.4, 16.6; not shown in table), but 
we had no data on miscarriage or abortion. The association of ANA with parity might be 
underestimated, since the referent category is likely to include some women with no 
pregnancies or births and higher ANA due to autoimmune-related infertility. Many younger 
women in the U.S. are nulliparous by choice and the fraction of nulliparous women who are 
infertile should increase with age; but in our sample we saw no age-related increase in ANA 
among nulliparous women before age 60. Thus underestimation due to lack of data on 
autoimmune-related infertility may be negligible.
Parity was not associated with ANA prevalence in postmenopausal women, though evidence 
for a statistical interaction was modest. Different factors may contribute to the initiation and 
persistence of ANA across different life stages. Despite being older and more likely to be 
parous, postmenopausal women had a lower overall ANA prevalence than premenopausal 
women. This finding suggests a role for endogenous hormones on ANA production. We 
stratified analyses of reproductive and hormonal risk factors based on this observation as 
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well as sample and data constraints. Stratified analyses are also supported by known effects 
of menopause and estrogen on immunity and autoimmunity (15, 35, 36). Estrogen receptors 
are expressed in most immune cells (37), but effects depend on receptor type and may be 
complex (38, 39). Estrogen can impact antibody-mediated immunity, including suppression 
of B-cell development (40). We saw no consistent patterns for exogenous estrogen use 
associated with ANA, with a complicated picture suggesting differences by menopause 
status. We noted higher ANA levels in the oldest premenopausal women (age 50+; Table 1), 
but a larger sample is needed to disentangle menopause status from age and hormone use, 
and to investigate perimenopausal factors.
Later age at menarche is associated with fewer lifetime menstrual cycles and lower estrogen 
levels (41, 42), so the observed association of late menarche age with ANA in 
postmenopausal women was unexpected. The finding was based on relatively few women 
with older menarche age and could be due to chance or an age-cohort effect. We did not test 
for interaction by menopause status. Age at menarche may be a marker for non-estrogen-
mediated effects on the immune system, e.g., perinatal factors (43, 44), early life infections 
(45) and social hardship (46). xenobiotics, infections and stress may impact immune 
development (47) and evidence is growing for a role of early life factors in autoimmune 
diseases (48–50). Together, these findings support further study of early life factors and 
autoimmunity.
Our study has limitations. A lack of data on autoimmune diseases other than RA limited our 
ability to rule out confounding by autoimmune diagnoses, which could influence 
reproductive history and the use of hormones. We saw no differences in ANA associations 
with parity and menarche age when women reporting RA or thyroid disease were excluded 
from analyses. Because self-report of RA and thyroid disease is sensitive, but not specific, 
the number of reported cases in our sample is higher than it would have been if we classified 
cases based on a more rigorous definition using available data on use of disease-specific 
medications (51–53). We chose to exclude all self-reported cases because reliance on current 
medication data would have missed cases in remission or those using less specific therapies. 
Although our main findings were robust to confounding and sensitivity analyses, 
generalizing results to the full NHANES sample and US population requires cautious 
interpretation given the lower response rate of older women in the examination (e.g., in 
1999–2001 93% of females overall and 72% of women age 80+;(54)) and exclusions for 
blood draws (e.g., chemotherapy within the past 4 weeks).
Cross-sectional analyses cannot address the timing of ANA occurrence relative to 
exposures. More than 10% of adolescent girls had a positive ANA, suggesting the 
importance of inherent and early life risk factors for autoimmunity. Genetic predisposition to 
ANA is supported by higher prevalence of ANA in family members of patients with 
autoimmune diseases (55–57), but family history of autoimmune diseases was not collected 
in NHANES. We also lacked data on infertility, pregnancy loss, mode of delivery, or other 
pregnancy characteristics, such as pre-eclampsia (58, 59). We did not examine the influence 
of circadian or monthly variation in ANA given the long half-life of IgG antibodies (2–4 
weeks).
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Some misclassification of menopause status and hormone use is likely, due to diminishing 
accuracy of recall over time and more systemic sources of bias, such as the assumptions 
regarding menopause status in women with simple hysterectomy with one or both ovaries 
retained (60–62). Most women with natural menopause in this sample reported having their 
last menstrual period before age 55, so using this cut-point for determining menopause 
status in women with simple hysterectomy is likely to have correctly classified the majority 
of older postmenopausal women. But this cut-point is insensitive for identifying younger 
postmenopausal women with simple hysterectomy, who could have been incorrectly 
included in the premenopausal category, especially if hysterectomy is associated with earlier 
ovarian failure (63). However, our findings appeared unchanged in sensitivity analyses 
reclassifying younger women with a simple hysterectomy from the premenopausal to 
postmenopausal category.
If there were birth cohort effects on ANA and estrogen use, changes in estrogen use and 
formulations could possibly create bias. To address changes in hormone therapy over the 
years of this study, we adjusted for collection cycle, but saw no confounding. We saw no 
confounding by smoking, but did not adjust for other environmental exposures (e.g., 
occupation, medications), and confounding by these factors is expected to be minimal given 
the lack of established associations and/or rarity of most of these factors. Little is known 
about environmental factors associated with ANA; plausible candidates include immune 
modifying factors such as vitamin D and endocrine disrupting chemicals that may also be 
related to reproductive health (64–66).
Conclusions
Our results suggest childbearing may play an important role in initial antigen stimulation or 
breaking tolerance to self-antigens, contributing to the development of ANA. Although we 
saw no evidence that exogenous estrogens were associated with ANA prevalence, our 
findings do not rule out estrogen as a potential modifier of autoimmunity. One recent study 
of breast cancer in postmenopausal women reported an elevation of tumor autoantibodies 
only in women who had not taken hormone replacement therapy (67). Given role of 
reproductive and hormonal factors in many cancers, these characteristics will be important 
to consider in future studies of autoimmunity and cancer.
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Figure 1. Prevalence of ANA by age depends on parity
Weighted ANA prevalence estimates and 95% confidence intervals
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Figure 2. Parity explains age-associated increase in ANA prevalence in women ages 12–59, but 
not in those ages 60+
Prevalence Odds Ratios (POR) were estimated by survey logistic regression for increasing 
decade of age; the trend test for age by ANA is shown.
1Estimates shown in the upper panel are adjusted for race/ethnicity and poverty-index-ratio
2Estimates shown in the lower panel are also adjusted for parity in women ages 12–59 and 
parity plus age at menarche in women ages 60 and older.
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